Clinical paper

Cost-effectiveness of extracorporeal cardiopulmonary resuscitation for refractory out-of-hospital cardiac arrest: A modelling study

Tan N Doan\textsuperscript{a,b,*}, Stephen Rashford\textsuperscript{a}, Jason Pincus\textsuperscript{c}, Emma Bosley\textsuperscript{a,d}

Abstract

Background: Extracorporeal cardiopulmonary resuscitation (E-CPR) is a method of CPR that passes the patient’s blood through an extracorporeal membrane oxygenation (ECMO) device to provide mechanical haemodynamic and oxygenation support in cardiac arrest patients who are not responsive to conventional CPR (C-CPR). E-CPR is being adopted rapidly worldwide despite the absence of high quality trial data and its substantial cost. Published cost-effectiveness data for E-CPR are scarce.

Methods: We developed a mathematical model to estimate the cost-effectiveness of E-CPR relative to C-CPR in adult patients with refractory out-of-hospital cardiac arrest (OHCA). The model was a combination of a decision tree for the acute treatment phase and a Markov model for long-term periods. Cost-effectiveness was evaluated from the Australian health system perspective over lifetime. Cost-effectiveness was expressed as Australian dollars (AUD, 2021 value) per quality-adjusted life year (QALY) gained. Variables were parameterised using published data. Probabilistic and univariate sensitivity analyses were performed.

Results: The incremental cost-effectiveness ratio (ICER) of E-CPR was estimated to be AUD 45,716 per QALY gained over lifetime (95% uncertainty range 22,102–292,904). The cost-effectiveness of E-CPR was most sensitive to the outcome of the therapy.

Conclusion: E-CPR has median ICER that is below common accepted willingness-to-pay thresholds. Local factors within the health care system need to be considered to determine the feasibility of implementing an effective E-CPR program.

Keywords: Cost-effectiveness, ECMO, E-CPR, Out-of-hospital cardiac arrest

Introduction

Extracorporeal cardiopulmonary resuscitation (E-CPR) is an emerging resuscitative therapy for cardiac arrest patients who are refractory (not responsive) to conventional CPR (C-CPR). This method uses extracorporeal membrane oxygenation (ECMO) to provide mechanical haemodynamic and oxygenation support whilst awaiting definitive treatment and recovery of effective cardiac output. Although there are inconsistencies in the reported effectiveness of E-CPR, there is emerging evidence of improved outcomes in carefully selected patients for E-CPR. To date, Belohlavek et al.\textsuperscript{1} and Yannopoulos et al.\textsuperscript{2} are the only randomised controlled trials on E-CPR (both are single centre, open-label). Belohlavek et al.\textsuperscript{1} included a total of 256 out-of-hospital cardiac arrest (OHCA) patients and found that E-CPR did not significantly improve favourable neurological outcome at 180 days compared to C-CPR. In contrast, Yannopoulos et al.\textsuperscript{2} included a total of 36 OHCA patients and reported higher rates of survival to hospital discharge among those receiving E-CPR than C-CPR (43 versus 7%). Furthermore, a number of small observational studies on E-CPR reported improved survival and neurological outcomes in both OHCA and in-hospital cardiac arrest (IHCA).\textsuperscript{3,4}

International guidelines recommend that E-CPR may be considered as a rescue therapy for selected cardiac arrest patients for whom the suspected cause of the arrest is potentially reversible when C-CPR is failing (weak recommendation, very low certainty of evidence).\textsuperscript{10,11} Despite limited evidence and the absence of high quality trial data, the adoption of E-CPR has increased rapidly. Annual E-CPR episodes among adult patients increased over 10-fold, from 35 in 2003 to over 400 in 2014 worldwide.\textsuperscript{12} During the same period, the number of healthcare

* Corresponding author at: Queensland Ambulance Service, 125 Kedron Park Road, Kedron, QLD 4031, Australia.
E-mail address: tan.doan@uqconnect.edu.au (T.N Doan).
https://doi.org/10.1016/j.resplu.2022.100309
Received 27 July 2022; Received in revised form 6 September 2022; Accepted 14 September 2022

2666-5204/© 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
centres that performed E-CPR increased 12-fold, from 8 to 98 centres globally.12

Most healthcare systems around the world operate in resource constrained environments. E-CPR is resource-intensive; accordingly, quantifying its cost-effectiveness and identifying circumstances in which it provides the most value for money is essential. Data on the cost-effectiveness of E-CPR are scarce despite the rapid adoption of this technology. A limited number of studies in Japan,13 Canada,14 the United States,15 the Netherlands,16 and Australia17 found that E-CPR is cost-effective in both OHCA and IHCA. These studies are subject to a number of limitations including incorporation of only resource use during the acute in-hospital phase, assumption of no survivor in C-CPR patients, no consideration of changes in neurological status after discharge, not including data from the Yannopoulos et al.2 and Belohlavek et al.1 trials, and short time horizon. Owing to these limitations and the pressing need for further evidence, we performed a cost-effectiveness analysis of E-CPR versus C-CPR in refractory OHCA patients from the perspective of the Australian healthcare system. We adopted a lifetime horizon and included costs and outcomes of both acute in-hospital and long-term periods.

Methods

Model description

We developed a model in TreeAge Pro (version 2020; TreeAge Software Inc., Williamstown, MA, USA) to estimate and compare the costs, health outcomes (quality-adjusted life years, QALYs) and cost-effectiveness of E-CPR versus C-CPR. We considered a hypothetical cohort of adult OHCA patients who were aged between 18 and 75 years,7,18 refractory to C-CPR, eligible for E-CPR and transported to an ECMO-capable hospital. Fig. 1 shows a schematic presentation of the model. The model structures and health states are the same for both E-CPR and C-CPR; however, epidemiological and clinical input values are unique to each group. Input values for the model were derived from published literature and are presented in Table 1.

The model is a combination of a decision tree for the acute in-hospital phase following the cardiac arrest event and for a short-term period (3 months after hospital discharge), and a Markov model for long-term follow-up (3 months after discharge to 10 years, and after 10 years). We modelled the acute in-hospital phase in which each patient was assigned to either E-CPR or C-CPR, and discharged into one of the four cerebral performance category (CPC) scores (CPC-1, CPC-2, CPC-3, CPC-4) or death.19 We accounted for changes (improvement or worsening) of CPC scores within the term periods.

Conversion of cost data from past years to year 2021 value was done using the following formula: Cost in 2021 value = (Cost in past year value) × (Consumer price index 2021/Consumer price index past year). Cost of E-CPR during acute treatment was estimated to be AUD 60,197 and included all elements attributed to the patient’s episode of care from time of cardiac arrest to hospital discharge or death as described in Dennis et al.17 Complications due to E-CPR were assumed to incur an additional cost of AUD 3,645.17 Due to the lack of data specific for cardiac arrest and as per previous studies,20 annual long-term cost of CPC-1 and CPC-2 survivors was assumed to be the same as that estimated from Australian patients with ischaemic heart disease, at AUD 4,965.25 Like previous studies,20 annual ongoing cost of CPC-3 and CPC-4 survivors was assumed to be the same as first-ever ischaemic stroke patients in Australia, estimated to be AUD 5,928.25 We defined incremental cost-effectiveness ratios (ICERs) as additional cost per QALY gained from E-CPR relative to C-CPR. Given that Australia does not mandate a willingness-to-pay (WTP) threshold, we did not adopt one in our study. Rather, we presented numerical results of the ICERs so that determination of the cost-effectiveness of E-CPR can be made against any nominal WTP value.

Uncertainty and sensitivity analysis

Uncertainty analysis was performed with Monte Carlo simulation (10,000 iterations) to randomly sample parameters from their distributions (Table 1). We reported 95% uncertainty ranges around projected point estimates. Univariate sensitivity analysis was also carried out to understand the key ICER drivers. The variables that were considered in the univariate sensitivity analysis were E-CPR cost, cost of E-CPR complications, annual long-term cost of survivors, probability of death due to E-CPR complications, probability of E-CPR patients discharged with CPC-1, assumption of E-CPR and C-CPR having the same probabilities of changes in CPC scores within 3 months after discharge, and discount rate.

Results

Table 2 shows the projected costs and health outcomes of the two therapies. The ICER of E-CPR relative to C-CPR was AUD 45,716.
per QALY gained (95% uncertainty range 22,102–292,904). The
cost-effectiveness plane for the ICERs is presented in Fig. 2,
highlighting the uncertainty around the results due to simultaneous vari-
ations in input values. The cost-effectiveness acceptability curve
(Fig. 3) represents the probability of E-CPR being cost-effective rel-
ative to C-CPR over a range of WTP thresholds. The curve shows
that E-CPR was more likely to be cost-effective than C-CPR at any
WTP threshold that was above AUD 46,700 per QALY gained. Uni-
ivariate sensitivity analysis is shown in Fig. 4. The cost-effectiveness
of E-CPR was most sensitive to the outcome of the therapy, mod-
elled through the proportion of patients discharged with CPC-1.
There was an inverse relationship between the cost-effectiveness
of E-CPR and its outcome. Threshold analysis in Supplementary
Fig. S1 shows the ICER corresponding to each of the simulated val-
ues of the probability of E-CPR patients discharged with CPC-1. For
example, the ICER would exceed AUD 100,000 per QALY gained
when the probability of CPC-1 is below 6.0%.

Discussion

We found that E-CPR has an estimated ICER (AUD 45,716 per
QALY gained) that is below current accepted WTP thresholds inter-
nationally (Supplementary Table S2).13,14,20,26–28 Whilst Australia
does not have an explicit WTP threshold, it requires evidence that
a new medical technology represents value for money before it is
considered for government subsidies, and a number of countries
mandate a WTP threshold (Supplementary Table S2).13,14,20,26–28
The World Health Organization’s Choosing Interventions that are
Cost–Effective (WHO-CHOICE) suggests that an intervention that
costs less than three times the national annual gross domestic pro-
duct (GDP) per capita is considered cost-effective, and less than
one GDP per capita highly cost-effective.29 In 2021, GDP per capita
in Australia was AUD 82,599.30 Our estimated ICER (AUD 45,716
per QALY gained) is below all of the aforementioned thresholds.
For comparison, our ICER for E-CPR is lower than that for some

---

Fig. 1 – Schematic presentation of the model. C-CPR, conventional cardiopulmonary resuscitation; CPC, cerebral
performance category; E-CPR, extracorporeal cardiopulmonary resuscitation.
| Variable                                      | Base-case value | Uncertainty range | Distribution | Reference for base-case | Reference for range |
|-----------------------------------------------|-----------------|-------------------|--------------|-------------------------|---------------------|
| Age of cohort at start                        | 18–75 years     |                   | Triangular   | 7,18                    |                     |
| Male                                          | 79%             | 70–90%            | Triangular   | 7                       | 3,12                |
| Probability of significant E-CPR complications | 8.6%            | 0–32%             | Triangular   | 7                       | 4,6,34              |
| Probability of death due to E-CPR complications | 6.9%            | 4.1–11.2%         | Triangular   | 35                      | 35                  |
| CPC score at discharge                         |                 |                   |              |                         |                     |
| E-CPR                                         |                 |                   |              |                         |                     |
| CPC-1                                         | 13.5%           | 9.8–30.6%         | Triangular   | 19                      | 1,7,20              |
| CPC-2                                         | 1.9%            | 0–3.8%            | Triangular   | 19                      | 2,3,20              |
| CPC-3                                         | 0%              | 0–3.8%            | Triangular   | 19                      | 3                   |
| CPC-4                                         | 1.9%            | 0–11.5%           | Triangular   | 19                      | 3                   |
| Death                                         | 82.7% (complement) |               |              | 19                      | 2,19                |
| C-CPR                                         |                 |                   |              |                         |                     |
| CPC-1                                         | 1.9%            | 0.6–18.2%         | Triangular   | 19                      | 1,3,20              |
| CPC-2                                         | 0%              | 0–1.3%            | Triangular   | 19                      | 3,20                |
| CPC-3                                         | 3.8%            | 1.9–4.2%          | Triangular   | 19                      | 3                   |
| CPC-4                                         | 15.4%           | 6.7% – 16.9%      | Triangular   | 19                      | 2,19                |
| Death                                         | 78.9% (complement) |               |              | 19                      |                     |
| CPC score at 3 months                         |                 |                   |              |                         |                     |
| E-CPR                                         |                 |                   |              |                         |                     |
| CPC-1 → CPC-1                                 | 100%            |                   |              | 7                       | 1,7,19              |
| CPC-2 → CPC-1                                 | 53.8%           | 53.8–100%         | Triangular   | 7                       | 2,20                |
| CPC-2 → CPC-2                                 | 46.2%           |                   | Complement   | 7                       |                     |
| CPC-3 → CPC-1                                 | 66.7%           |                   | 2            | 2                       |                     |
| CPC-3 → CPC-2                                 | 33.3%           |                   | 2            | 2                       |                     |
| CPC-3 → CPC-3                                 | 0%              |                   |              | 2                       |                     |
| CPC-4 → CPC-4                                 | 100%            | 0%                |              | 2                       | 19                  |
| CPC-4 → Death                                 | 0% (complement) |                   | Complement   | 19                      |                     |
| C-CPR                                         |                 |                   |              |                         |                     |
| CPC-1 → CPC-1                                 | 100%            |                   |              | 19                      |                     |
| CPC-2 → CPC-1                                 | 0%              |                   |              | 19                      |                     |
| CPC-2 → CPC-2                                 | 100%            |                   |              | 19                      |                     |
| CPC-3 → CPC-1                                 | 0%              |                   |              | 19                      |                     |
| CPC-3 → CPC-2                                 | 0%              |                   |              | 19                      |                     |
| CPC-3 → CPC-3                                 | 100%            |                   |              | 19                      |                     |
| CPC-4 → CPC-4                                 | 12.5%           |                   | Complement   | 19                      |                     |
| CPC-4 → Death                                 | 87.5%           | 87.5–100%         |              | 19                      | 2                   |
| CPC score after 3 months                      | Same as CPC score at 3 months |                   |              | 23                      |                     |
| Annual probability of background death        | Refer to Supplementary Table S1 |               |              |                        |                     |
| Utility scores                                |                 |                   |              |                         |                     |
| CPC-1                                         | 0.85            | 0.75–0.95         | Triangular   | 36                      | 20,37               |
| CPC-2                                         | 0.85            | 0.75–0.86         | Triangular   | 36                      | 20,37               |
| CPC-3                                         | 0.47            | 0.20–0.58         | Triangular   | 36                      | 20,37               |
| CPC-4                                         | 0.33            | 0.10–0.47         | Triangular   | 37                      | 20,36               |
| Death                                         | 0               |                   |              |                          |                     |
| Time horizon                                  | Lifetime         |                   |              |                          |                     |
| Discount rate                                 | 3%              | 2–5%              | Univariate sensitivity analysis only |                        |                     |
| Costs                                         |                 |                   |              |                         |                     |
| Cost of E-CPR during acute treatment          | AUD 60,197      | ±10%              | Gamma (402.6; 0.007) | 17                      | Assumed             |
| Cost of complications related to E-CPR        | AUD 3,645       | ±10%              | Gamma (590.5; 0.162) | 17                      | Assumed             |
| Cost of C-CPR during acute treatment          | AUD 17,159      | ±10%              | Gamma (363.5; 0.021) | 17                      | Assumed             |
| Annual long-term cost, CPC 1–2               | AUD 4,965       | ±10%              | Gamma (293.1; 0.059) | Assumed to be the same as ischaemic heart disease24 | Assumed             |
| Annual long-term cost, CPC 3–4               | AUD 5,928       | ±10%              | Gamma (390.5; 0.066) | Assumed to be the same as first-ever ischemic stroke25 | Assumed             |

AUD, Australian dollar; C-CPR, conventional cardiopulmonary resuscitation; CPC, cerebral performance category; E-CPR, extracorporeal cardiopulmonary resuscitation.
other expensive new medical technologies currently used in Australia such as pelvic exenteration (AUD 227,330 per QALY gained compared to without the intervention),31 and nivolumab for the treatment of renal cell carcinoma (AUD 266,871 per QALY gained compared to everolimus).32

Our median ICER estimate supports findings of empirical studies that E-CPR for eligible refractory OHCA patients is cost-effective from a health system perspective. In Canada, E-CPR was found to be cost-effective at CAD 28,792 per life year gained (2019 value, ~AUD 31,383), assuming a WTP threshold of CAD 50,000.14 In Japan, the ICERs of E-CPR ranged from JPY 2,619,692 (2010 value, ~AUD 32,547)13 to USD 16,246 (2016 value, ~AUD 21,864)13 per QALY gained. The authors concluded that the treatment was cost-effective using a WTP threshold of JPY 5,000,000–6,000,000 (~AUD 59,000–70,000).13,20 In the United States, Bharmal et al.15 estimated that E-CPR cost USD 56,156 per QALY gained (2018 value, ~AUD 75,234) for OHCA and IHCA combined, suggesting the therapy was cost-effective using a contemporary WTP threshold of USD 150,000.15 To date, Dennis et al.17 is the only published cost-effectiveness study in the Australian setting. The authors reported an ICER of AUD 25,212 per QALY gained for OHCA and IHCA combined (2016 value) and concluded that ICER was cost-effective against common accepted WTP thresholds. While the acute costs of E-CPR and C-CPR in our study were derived from this study, there are some noticeable differences between our analysis and Dennis et al.17 Unlike Dennis et al.17 which assumed no survivor among C-CPR patients, we allowed for the fact that C-CPR patients may survive cardiac arrest, even with favourable neurological outcomes.2,3,19,20 Furthermore, Dennis et al.17 was limited to resource usage up to the point of hospital discharge whereas we accounted for long-term healthcare costs. Dennis et al.17 did not allow for changes in neurological functions after discharge; whereas we accounted for such possibility. To date, patient selection for E-CPR remains a contentious issue. Although variation exists, common criteria include adults (18 – up to 75 years), witnessed arrest with reversible causes, initial shockable rhythm, and estimated transfer time <30 minutes or total low-flow period <60 minutes.2,7,33 Parameterisation for our base-case analysis was primarily based on Kim et al.,19 which did not consider initial arrest rhythm or transfer/low-flow time in their selection of patients. Had Kim et al.19 adopted more stringent criteria, the clinical outcomes would likely have been better, and our estimated cost-effectiveness would have been more favourable.

We found that the cost-effectiveness of E-CPR was most sensitive to the outcome of the therapy. Nevertheless, at the lower limit of the modelled effectiveness of E-CPR (proportion of patients discharged with CPC-1), the median ICER (AUD 63,225 per QALY gained) remained to be within the WTP thresholds adopted in international literature and well below GDP per capita for Australia (AUD 82,599). For the median ICER to exceed a hypothetical WTP threshold of one GDP per capita (AUD 82,599), the proportion of E-CPR
patients discharged with CPC-1 would need to be as low as 10%, which is lower than that reported in observational studies and clinical trials.\textsuperscript{1,2,7,19,20} This suggests that more relaxed patient selection criteria may be feasible while still ensuring that the intervention is cost-effective. Nevertheless, such new criteria need to be evaluated prior to adoption.

This study is subject to a number of limitations. It was conducted from a health system perspective, and therefore did not incorporate indirect costs such as loss of productivity. Cost of destination therapies after E-CPR (e.g. long-term ventricular assist device, heart transplant) was not considered. Our study modelled E-CPR performed in the hospital setting, and did not cover rendezvous and pre-hospital E-CPR. Like other studies in this area, we did not incorporate costs associated with E-CPR training and maintenance due to the lack of data. We did not consider the potential gain in organ donation as an outcome associated with E-CPR. The inclusion of organ donation would further improve the cost-effectiveness of E-CPR. Although we used the best available and most relevant published data to parameterise our model, our results may not be generalisable to settings in which practices and costs are very different from those we used. In the absence of long-term cost data specific to OHCA survivors, we followed previous studies\textsuperscript{20} and assumed that those costs were similar to ischaemic heart disease patients (for CPC-1 and CPC-2 survivors) and stroke survivors (for CPC-3 and CPC-4 survivors). Nevertheless, our results were not sensitive to such an assumption. Like most studies in this topic, we looked at the cost-effectiveness of E-CPR from a purely probabilistic and fiscal perspective. Regardless of how cost-effective the intervention appears to be from a theoretical standpoint, health facilities need to consider their own environment to determine whether it is feasible to deliver an effective E-CPR system at a local level needs to be assessed, taking into account all relevant factors within the studied health care system.

Conclusions

E-CPR has median ICER that is below common accepted WTP thresholds. Larger trials and trial-based economic evaluations are needed. The feasibility to deliver an effective E-CPR program at a local level needs to be assessed, taking into account all relevant factors within the studied health care system.

CRediT authorship contribution statement

Tan N Doan: Conceptualization, Data curation, Writing – original draft. Stephen Rashford: Conceptualization, Supervision, Writing – review & editing. Jason Pincus: . Emma Bosley: Conceptualization, Supervision, Writing – review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.resplu.2022.100309.
REFERENCES

1. Belohlavek J, Smalcova J, Rob D, et al. Effect of intra-arrest transport, extracorporeal cardiopulmonary resuscitation, and immediate invasive assessment and treatment on functional neurologic outcome in refractory out-of-hospital cardiac arrest: a randomized clinical trial. JAMA 2022;327:737–47.

2. Yannopoulos D, Bartos J, Raveendran G, et al. Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomised controlled trial. Lancet 2020;396:1807–16.

3. Sakamoto T, Morimura N, Nagao K, et al. Extracorporeal cardiopulmonary resuscitation versus conventional cardiopulmonary resuscitation in adults with out-of-hospital cardiac arrest: a prospective observational study. Resuscitation 2014;85:762–8.

4. Dennis M, Buscher H, Gattas D, et al. Prospective observational study of mechanical cardiopulmonary resuscitation, extracorporeal membrane oxygenation and early reperfusion for refractory cardiac arrest in Sydney: the 2CEER study. Crit Care Resusc 2020;22:26–34.

5. Maekawa K, Tanno K, Hase M, Mori K, Asai Y. Extracorporeal cardiopulmonary resuscitation for patients with out-of-hospital cardiac arrest: a propensity-matched study and predictor analysis. Crit Care Med 2013;41:1186–96.

6. Yannopoulos D, Bartos JA, Martin C, et al. Minnesota Resuscitation Consortium’s advanced perfusion and reperfusion cardiac life support strategy for out-of-hospital refractory ventricular fibrillation. J Am Heart Assoc 2016;5:e003732.

7. Bartos JA, Frascone RJ, Conterato M, et al. The Minnesota mobile extracorporeal cardiopulmonary resuscitation consortium for treatment of out-of-hospital refractory ventricular fibrillation: Program description, performance, and outcomes. EClinicalMedicine 2020;29–30:100632.

8. Siao F-Y, Chiu C-C, Chiu C-W, et al. Managing cardiac arrest with refractory ventricular fibrillation in the emergency department: Conventional cardiopulmonary resuscitation versus extracorporeal cardiopulmonary resuscitation. Resuscitation 2015;92:70–6.

9. Chou T-H, Fang C-C, Yen Z-S, et al. An observational study of extracorporeal CPR for in-hospital cardiac arrest secondary to myocardial infarction. Emerg Med J 2014;31:441–7.

10. Panchal AR, Bartos JA, Cabanas JG, et al. Part 3: Adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation 2020;142:S366–468.

11. Soar J, Böttiger BW, Carli P, et al. European Resuscitation Council Guidelines 2021: Adult advanced life support. Resuscitation 2021;161:115–51.

12. Richardson ASC, Schmidt M, Bailey M, Pellegrino VA, Rycus PT, Pitlcher DV. ECMO Cardio-Pulmonary Resuscitation (ECPR), trends in survival from an international multicentre cohort study over 12-years. Resuscitation 2017;112:34–40.

13. Kawashima T, Uehara H, Miyagi N, et al. Impact of first documented rhythm on cost-effectiveness of extracorporeal cardiopulmonary resuscitation. Resuscitation 2019;140:74–80.

14. Ontario Health (Quality). Extracorporeal membrane oxygenation for cardiac indications in adults: a health technology assessment. Ont Health Technol Assess Ser 2020;20:1–121.

15. Bharmal MI, Venturini JM, Chua RFM, et al. Cost-utility of extracorporeal cardiopulmonary resuscitation in patients with cardiac arrest. Resuscitation 2019;136:126–30.

16. Gravesteijn BY, Schlupe M, Voormolen DC, et al. Cost-effectiveness of extracorporeal cardiopulmonary resuscitation after in-hospital cardiac arrest: A Markov decision model. Resuscitation 2019;143:150–7.

17. Dennis M, Zmudzki F, Burns B, et al. Cost effectiveness and quality of life analysis of extracorporeal cardiopulmonary resuscitation (ECPR) for refractory cardiac arrest. Resuscitation 2019;139:49–56.

18. Bartos JA, Carlson K, Carlson C, et al. Surviving refractory out-of-hospital ventricular fibrillation cardiac arrest: Critical care and extracorporeal membrane oxygenation management. Resuscitation 2018;132:47–55.

19. Kim SJ, Jung JS, Park JH, Park JS, Hong YS, Lee SW. An optimal transition time to extracorporeal cardiopulmonary resuscitation for predicting good neurological outcome in patients with out-of-hospital cardiac arrest: a propensity-matched study. Crit Care 2014;18:535.

20. Matsuoka Y, Goto R, Atsumi T, et al. Cost-effectiveness of extracorporeal cardiopulmonary resuscitation for out-of-hospital cardiac arrest: A multi-centre prospective cohort study. Resuscitation 2020;157:32–8.

21. Tanaka D, Hirose H, Cavarocchi N, Entwistle JW. The Impact of vascular complications on survival of patients on venoarterial extracorporeal membrane oxygenation. Ann Thorac Surg 2016;101:1729–34.

22. Chocron R, Fahrenbruch C, Yin L, et al. Association between functional status at hospital discharge and long-term survival after out-of-hospital-cardiac-arrest. Resuscitation 2021;164:30–7.

23. Australian Bureau of Statistics. Life tables 2018–2020. Available at https://www.abs.gov.au/statistics/people/population/life-tables/latest-release.

24. Cobiac LJ, Magnus A, Barendregt JJ, Carter R, Vos T. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study. BMC Public Health 2012;12:398.

25. Gloede TD, Halbach SM, Thrift AG, Dewey HM, Pfaff H, Cadilhac DA. Long-term costs of stroke using 10-year longitudinal data from the North East Melbourne Stroke Incidence Study. Stroke 2014;45:3389–94.

26. Wang S, Gum D, Merlin T. Comparing the ICERs in medicine reimbursement submissions to NICE and PBAC - Does the presence of an explicit threshold affect the ICER proposed? Value Health 2018;21:938–43.

27. Braithwaite RS, Meltzer DO, King Jr JT, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008;46:349–56.

28. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. New Engl J Med 2014;371:796–7.

29. Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ 2015;93:119–24.

30. The World Bank. GDP per capita – Australia 2021. Available at https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?end=2021&start=2021.

31. Koh CE, Badgery-Parker T, Salkeld G, Young JM, Heriot AG, Solomon MJ. Cost-effectiveness of pelvic exenteration for locally advanced malignancy. Br J Surg 2016;103:1548–56.

32. Kim H, Goodall S, Liew D. Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price. J Med Econ 2021;24:893–9.

33. Hutton A, Abu-Habsa M, Burns B, et al. Early ECPR for out-of-hospital cardiac arrest: Best practice in 2018. Resuscitation 2018;130:44–8.

34. Wong JK, Melvin AL, Joshi DJ, et al. Cannulation-related complications on veno-arterial extracorporeal membrane oxygenation: prevalence and effect on mortality. Arif Organ 2017;41:827–34.
35. Vaquer S, de Haro C, Peruga P, Oliva JC, Artigas A. Systematic review and meta-analysis of complications and mortality of veno-venous extracorporeal membrane oxygenation for refractory acute respiratory distress syndrome. Ann Intensive Care 2017;7:51.

36. Gates S, Lall R, Quinn T, et al. Prehospital randomised assessment of a mechanical compression device in out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised trial and economic evaluation. Health Technol Assess 2017;21:1–176.

37. Ginsberg GM, Kark JD, Einav S. Cost-utility analysis of treating out of hospital cardiac arrests in Jerusalem. Resuscitation 2015;86:54–61.